Scientific publications 

Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two cases

Panizo C, Patiño A, Lecumberri R, Calasanz MJ, Odero MD, Bendandi M, Rocha E.
Department of Hematology, University Clinic of Navarra, University of Navarra, Navarra, Spain.

Magazine: Cancer Genetics and Cytogenetics

Date: Sep 1, 2003

Cell Therapy Area [SP] Clinical Genetics Unit [SP] Hematología y Hemoterapia [SP]

Acute promyelocytic leukemia (APL) represents a biologic and clinically well-defined subtype of acute nonlymphocytic leukemia with specific morphologic and karyotypic characteristics.

Although secondary leukemia and myelodysplastic syndromes (MDS) are the most frequent secondary neoplasms following chemotherapy for acute leukemia, their development after complete remission in patients with APL is uncommon. We describe the clinical and genetic features of two APL patients who achieved CR after chemotherapy and all-trans retinoid acid treatment and subsequently developed a MDS. Therapy-related MDS karyotype changes such as abnormalities of chromosomes 5 and 7 were found in the cytogenetic analysis.

Since TP53 alteration was detected in one case, possible implications of these findings in the onset of MDS are discussed.

CITATION  Cancer Genet Cytogenet. 2003 Jun;143(2):178-81

you maybe interested


The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra


The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra


Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra